Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Income from Continuing Operations (2016 - 2025)

Sangamo Therapeutics has reported Income from Continuing Operations over the past 16 years, most recently at 37419000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 37419000.0 for Q4 2025, down 59.94% from a year ago — trailing twelve months through Dec 2025 was 122932000.0 (down 25.52% YoY), and the annual figure for FY2025 was 122932000.0, down 25.52%.
  • Income from Continuing Operations for Q4 2025 was 37419000.0 at Sangamo Therapeutics, down from 34930000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for SGMO hit a ceiling of 21133000.0 in Q1 2023 and a floor of 114506000.0 in Q2 2023.
  • Median Income from Continuing Operations over the past 5 years was 43596000.0 (2022), compared with a mean of 42466750.0.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 3063.26% in 2021 and later soared 148.01% in 2023.
  • Sangamo Therapeutics' Income from Continuing Operations stood at 37496000.0 in 2021, then plummeted by 38.61% to 51973000.0 in 2022, then dropped by 16.01% to 60295000.0 in 2023, then skyrocketed by 61.2% to 23396000.0 in 2024, then plummeted by 59.94% to 37419000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 37419000.0 (Q4 2025), 34930000.0 (Q3 2025), and 19986000.0 (Q2 2025) per Business Quant data.